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Background: Endometrial carcinoma is one of the most common female cancers in developed countries. Disease
stage is associated with the risk of disease relapse after radical treatment. Typically, the risk of disease relapse peaks
at 3 years from local radical treatment and then diminishes over time, so that late relapses (i.e., from year 5
afterward) are extremely infrequent. Here, we report two cases of women with endometrial cancer who developed
a disease relapse more than 15 years after radical treatment. A review of the literature revealed other seven reports
of women with relapse from endometrial cancer occurring more than 10 years after radical treatment.
Case presentation: Case report 1 is a 56-year-old woman with an endometrioid cancer who underwent a
hysterectomy with bilateral salpingo-oophorectomy in 1998. She relapsed in the lung in 2014, 16 years from radical
surgery. Case report 2, a 75-year-old woman, with an endometrioid cancer, was treated by hysterectomy with
bilateral salpingo-oophorectomy and adjuvant radiotherapy. The disease relapse in the lung was detected in 2019,
22 years from radical treatment.
Conclusion: Although guidelines do not support oncological follow-up beyond 5 years from surgery, oncologists
should consider late recurrence of endometrial carcinoma in the differential diagnosis of women presenting with
metastases of uncertain origin and prior history of this disease.
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Endometrial carcinoma represents the sixth most com-
mon neoplasm among women worldwide, and the fourth
most common in developed countries [1]. Approxi-
mately 98,000 new cases of endometrial carcinoma and
23,000 related deaths are registered in Europe every year.
The prognosis of this neoplasm is strictly related to the
disease stage at diagnosis. According to the International
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prognosis after surgery and adjuvant radiotherapy, with
a 5-year survival rate of 80-90% and a recurrence rate
between 3 and 15% [3, 4]. Long-term survival rapidly de-
creases below 25% in advanced stages (FIGO III and IV).
Almost all disease relapses occur within 5 years from
radical treatment, with increased frequency in the first 3
years [5]. Just a few cases of relapse beyond year five are
reported in the medical literature. Here, we describe two
women with endometrial cancer who developed systemic
relapse after 16 and 22 years from radical surgery and
provide a brief overview of the medical literature on
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We describe the clinical history of two patients with late
recurrence of endometrial cancer, treated, and followed
at our center. We also performed a systematic PubMed
search for case reports of case series of late (beyond year
ten from treatment) systemic relapse from endometrial
cancer. We focused only on recurrences from endomet-
rial cancer occurring after radical surgery and excluded
new primary endometrial cancers developing in extra-
uterine endometriosis many years after a hysterectomy
performed for endometriosis.
Case report 1
A 56-year-old woman underwent ultrasonography of the
abdomen in 1998 because of the appearance of abdom-
inal swelling and pain. The exam revealed a pelvic mass,
which was then confirmed to be uterine by an explora-
tory laparoscopy. Laparoscopy was therefore converted
in laparotomy, and a hysterectomy with bilateral
salpingo-oophorectomy without lymphadenectomy was
performed. Histological examination of the surgical sam-
ple revealed a well-differentiated, estrogen receptor [ER]
positive, endometrioid cancer with negative surgical
margins. Preoperative staging performed with a total-
body CT scan showed no distance metastasis, and FIGO
stage was IB according to the 1996 edition [6]. Surgery
was radical and, according to the guidelines at the time,
the patient was considered low risk of relapse, then no
adjuvant treatment was prescribed. Oncological follow-
up was carried out with semestral clinical examination
and CT scan, and it was negative during the following 5
years. In October 2014, the patient developed a chronic
cough and underwent a CT scan of the chest, which re-
vealed a 90mm in diameter mass in the upper lobe of
the right lung (Fig. 1). Full staging with total-body CTFig. 1 CT scan of chest performed in October 2014 because of the
persistence of chronic cough, showing a mass of 90 mm in the right
upper lobe (case report 1)scan, gastroscopy, and colonoscopy did not show a pri-
mary tumor or other metastases. Bronchoscopy with bi-
opsy revealed endometrial carcinoma cells staining
positively for the ER. Immunostaining for Ki-67 was
positive in 30% of malignant cells. Following multidiscip-
linary evaluation, the patient underwent neoadjuvant
chemotherapy with carboplatin area under the curve
(AUC) 5 plus paclitaxel 175mg/m2 every 3 weeks. The
first tumor imaging performed after three cycles of
chemotherapy showed a partial response. Upon comple-
tion of 6 cycles of neoadjuvant chemotherapy, in Febru-
ary 2015, the patient underwent right lung lobectomy.
Histopathology confirmed metastasis from endometrial
carcinoma, which was ER positive, paired box 8 [PAX8]
positive, thyroid transcription factor 1 [TTF-1] negative,
and CDX2 negative (Fig. 2). Surgical margins were nega-
tive. After surgery, the patient was prescribed endocrine
therapy with tamoxifen 20 mg/day. At the time of this
writing, the patient is continuing hormonal treatment
and oncological follow-up and remains disease free.
Case report 2
A 75-year-old woman underwent hysterectomy with
bilateral salpingo-oophorectomy and lymphadenec-
tomy because of the accidental discovery of a pelvic
mass in 1997. Histological examination of the surgical
sample showed a grade 1 differentiated, ER positive,
PAX8 positive, TTF-1 negative, and CA125 negative
endometrioid carcinoma. Preoperative staging per-
formed with total-body CT scan showed no distance
metastasis, and FIGO stage was II according to the
1996 edition [6]. According to Italian guidelines at
the time, the patient underwent adjuvant radiotherapy
with 40 Gray delivered by external beams. The fol-
lowing 5 years of oncological follow-up, with semestral
clinical examination and CT scan, were uneventful. In
January 2019, the patient was admitted to the emer-
gency department of our hospital because of worsen-
ing dyspnea. While excluding pulmonary embolism, a
computed angiography of the chest showed a 28 mm
in diameter mass in the upper lobe of the right lung
(Fig. 3). A positron-emission tomography (PET) with
fludeoxyglucose showed intense uptake of the tracer
in the lung lesion (standardized uptake value [SUV]
12.2). Histopathology of a biopsy of the lesion re-
vealed endometrial carcinoma cells, which were ER
and PAX8 positive, and TTF1 and CA125 negative.
Because of no other systemic metastases, in March
2019, the patient underwent surgical resection of the
lesion. Histopathology confirmed the endometrial ori-
gin (ER and PAX8 positive, and TTF1, CDX2, and
CA125 negative) and showed clear surgical margins
(Fig. 4). After 4 months of follow-up, the patient de-
veloped a painful cutaneous node in the abdominal
Fig. 2 Histological examination of right lung lobectomy, showing tumoral cells colored with hematoxylin-eosin (a), positivity for estrogen
receptor (ER) (b), and negativity for thyroid transcription factor 1 (TTF-1) (c)
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scan showed a 45 mm in diameter lung mass near the
site of metastasectomy, a 33 mm in diameter node of
the abdominal wall, and other two smaller lesions in
the muscles of the abdominal wall. The cutaneous
node was surgically removed, and the histological
examination revealed metastasis from endometrialFig. 3 CT scan of chest performed in January 2019 to exclude
pulmonary embolism, showing a mass of 28 mm in the right upper
lobe (case report 2)carcinoma, ER and PAX8 positive, and TTF1, CDX2,
and CA125 negative. Vascular carcinoma microemboli
were observed in the surrounding adipose tissue. Be-
cause of systemic disease, our multidisciplinary team
decided for first-line chemotherapy, which consisted
of carboplatin AUC5 and paclitaxel 175 mg/m2 every
21 days. At the time of this writing, therapy is still
ongoing, 22 years after the first diagnosis of endomet-
rial carcinoma.
Brief review of literature
Systemic metastases from endometrial carcinoma usu-
ally develop within the first 3 years after radical treat-
ment, while long-term recurrences are possible but
uncommon [5]. Indeed, only a few cases of recur-
rences after more than 10 years after radical treatment
are described in literature. The first experience was
reported in 1987 by Lederman et al. A 47-year-old
woman who received an intracavitary radium implant
followed by radical hysterectomy for endometrial car-
cinoma. She developed a vaginal recurrence 26 years
after local treatment. Treatment consisted of vaginal
radiotherapy, after which the patient resumed follow-
up with no further events [7]. In 2001, Ito et al. de-
scribed a case of a 60-year old patient who under-
went surgical resection of suspected lung cancer.
However, histopathology revealed cells of adenoa-
canthoma, which were consistent with the diagnosis
Fig. 4 Histological examination of pulmonary metastasectomy, showing tumoral cells colored with hematoxylin-eosin (a), positivity for estrogen
receptor (ER) (b), positivity for paired box 8 (PAX8) (c), and negativity for thyroid transcription factor 1 (TTF-1) (d)
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when she had undergone radical hysterectomy. Sta-
ging workup showed no other sites of metastasis, and
the patient resumed the oncological follow-up with
no further events [8]. Lorenz et al. described a case
of late recurrence of endometrial cancer in the ab-
dominal scar of a patient who had undergone radical
hysterectomy and radiotherapy for endometrial carcin-
oma 14 years before. The mass, which was 80 mm in
diameter was surgically removed, and histopathology
confirmed the diagnosis of metastasis from endomet-
rial carcinoma [9]. Tsurumaki et al. described an un-
usual site of recurrence 11 years after radical
hysterectomy. A 72-year-old woman underwent rad-
ical hysterectomy for endometrioid carcinoma and a
lymph-node recurrence next to the left ureter 3 years
after. This recurrence was treated with radical exci-
sion and radiotherapy. Eleven years after hysterec-
tomy, the patient developed progressive left
hydronephrosis. A CT scan of the abdomen showed a
pelvic mass involving the left ureter. The patient
underwent a left nephroureterectomy with partial
cystectomy, and histopathology confirmed metastasis
from endometrioid carcinoma. The patient resumed
the follow-up after adjuvant radiotherapy [10]. In
2015, Yechieli et al. described a case of a 61-year-old
female who underwent a total abdominal hysterec-
tomy with bilateral salpingo-oophorectomy and lymphnode for an endometrioid adenocarcinoma. Adjuvant
external beam radiotherapy was performed, and the
patient remained disease free for 17 years until an iso-
lated vaginal cuff recurrence developed. The patient
underwent salvage high-dose-rate brachytherapy, after
which follow-up was resumed and continued until she
died from cancer-unrelated causes [11]. Another un-
usual site of metastasis was reported by Addison
et al., who described a case of a 62-year-old woman
who had undergone radical hysterectomy for endo-
metrial carcinoma in 2000. She needed emergency
surgery in 2010 because of an acute abdomen and
sepsis. Surgery consisted of laparotomy with appendi-
cectomy. The histological examination confirmed
appendicitis with peritonitis, but endometrial adeno-
carcinoma cells were also detected as an unexpected
finding. After recovery, the patient was referred to an
oncology team but received no further treatment [12].
Finally, in 2015, Franchello et al. reported the case
with the most extended interval between surgery and
relapse, 28 years. A 72-year-old woman with a history
of multiple neoplasms, including endometrial carcin-
oma, underwent hysterectomy for endometrial carcin-
oma in 1989. A screening colonoscopy performed in
2013 showed a rectal mass. Histopathology of a bi-
opsy of the rectal mass showed cancer cells of endo-
metrial origin. The patient underwent surgical
removal of the rectal mass and of a single liver
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workup. Histopathology confirmed that both lesions
were recurrences of endometrial carcinoma. No adju-
vant treatments were indicated, and further follow-up
was uneventful [13]. Table 1 summarizes the cases
described in this paragraph.
Discussion
The prognosis of endometrial carcinoma has constantly
been improving over the last decades [14]. While excel-
lent rates of survival can be achieved in patients with
low-stage disease treated with local treatment alone, the
addition of chemotherapy may reduce the risk of relapse
in patients at higher risk. Local or distant recurrence,
which usually occurs in the initial 3 years after local
treatment, remains a problem for a proportion of pa-
tients [5]. Conversely, because the risk relapse beyond 5
years is low, guidelines limit oncology follow-up to the
initial 5 years after local treatment [1]. In this paper, we
describe two cases of patients who developed very late
recurrences and were treated at our center. It is import-
ant to underline that these cancers were treated over 20
years ago according to guidelines that undergone several
updates over the following years. In particular, the strati-
fication of risk, critical as regards the decision about the
adjuvant treatment, nowadays is no longer based only on
FIGO staging and histological grade. In fact, different al-
gorithms have been developed with the aim to create a
risk stratification system based on several clinico-
pathological parameters, which include not only FIGO
stage and tumor differentiation grade but also age, histo-
type, depth of myometrial invasion, and lymphovascular
space invasion [15]. Anyway, with the two cases de-
scribed in this paper, the total of late relapses from
endometrial carcinoma published in the medical litera-
ture adds up to nine. Due to such a low number, it isTable 1 Cases of late recurrence of endometrial carcinoma reported








Lederman et al. 1987 47 Adenoacanthoma IA H
Ito et al. 2001 60 Adenoacanthoma IB H
Lorenz et al. 2004 73 Endometrial carcinoma IA H
Tsurumaki et al. 2009 72 Endometrioid
adenocarcinoma
II H
Yechieli et al. 2011 61 Endometrioid
adenocarcinoma
IC H
Addison et al. 2012 62 Endometrial carcinoma IB H
Franchello et al. 2015 72 Endometrioid
adenocarcinoma
IB H
Case report 1 56 Endometrial carcinoma IB H
Case report 2 75 Endometrial carcinoma II H
H hysterectomy, BSO bilateral salpingo-oophorectomy, L lymphadenectomy, CT chedifficult to identify predictors of late recurrence, which
can direct specific follow-up strategies. The median age
was 62 years. Overall, seven out of nine patients (78%)
were stage I FIGO, and the remaining two were stage II
FIGO. Histologically, two tumors were defined as
acanthomas, and the other seven are generically de-
scribed as “endometrial carcinoma” or as “endometrioid
adenocarcinoma,” the most frequent histological variant
of endometrial carcinoma [16]. Primary local treatment
consisted of hysterectomy in the four patients diagnosed
before 2009, and hysterectomy plus bilateral salpingo-
oophorectomy in the five patients diagnosed more re-
cently. The recurrence time spanned from 10 to 28
years, with three patients recurring after more than 20
years. A common feature of these cases is that patients
recurred with oligometastatic disease, and surgical re-
moval or local treatment of recurrent disease was feas-
ible in almost all cases, except the one described by
Addison et al. For seven patients, further follow-up after
local systemic treatment was uneventful. Only the two
patients described in this paper received systemic ther-
apy, one with neoadjuvant and the other with palliative
intent. Currently, histopathology and molecular path-
ology play a critical role in identifying prognostic factors
in several cancers. Even in endometrial cancer, the mo-
lecular pathology influences more and more the
decision-making process about surgery, the need for ad-
juvant therapy, and follow-up management [17]. Unfor-
tunately, the cases described here are few, and the
information on further histopathological and molecular
details are missing. Only the paper of Franchello et al.
provides some information about the immunophenotypi-
cal pattern of the neoplasm: the rectal recurrence of
endometrial carcinoma was positive for CK7, ER, antivi-
mentin antibody, and PAX8, and negative for CK20 and









Vagina 26 years Radiotherapy
Lung 17 years Surgery
Abdominal scar 14 years Surgery
+ L Ureter 11 years Surgery + radiotherapy
+ BSO + L Vagina 17 years Brachytherapy
+ BSO Appendix 10 years Surgery
+ BSO + L Rectum 28 years Surgery
+ BSO Lung 16 years Surgery + CT + HT
+ BSO + L Lung and soft tissues 22 years Surgery + CT
motherapy, HR hormone therapy
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we describe in this manuscript display similar immuno-
phenotypical features (ER and PAX8 positive and CDX2
negative). These immunohistochemical features usually
identify low-grade, slowly growing endometrial cancers
[20] and cannot be used to identify patients at risk for
late relapse. Intriguingly, ER-positive breast cancer can
recur systemically even after decades from surgery of
primary tumor [21]. This phenomenon is due to “cell
dormancy” and is less pronounced, if not absent, in
other subtypes of breast cancer. ER expression and me-
tabolism may influence the ability of endometrial cancer
cells to migrate and to enter a dormant status similarly
to breast cancer cells. Aging and related pro-
tumorigenic stimuli as chronic inflammation may
“awake” dormant cells and give rise to overt clinically
overt metastases [22].
Conclusion
Relapses of endometrial carcinoma rarely occur beyond
5 years from surgery. Yet, despite extremely rare, they
are possible. While a change in the follow-up policies is
not justified based on the very few case reports described
here, it is crucial to consider endometrial cancer relapse
in the differential diagnosis of metastases of unknown
origin in women with previous adenocarcinoma of the
endometrium, even if radical treatment has been per-
formed many years before.
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